{
    "clinical_study": {
        "@rank": "63894", 
        "arm_group": {
            "arm_group_label": "Cabazitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Cabazitaxel 25 mg/m\u00b2 intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To evaluate the safety of cabazitaxel (Jevtana) in patients with metastatic hormone\n      refractory prostate cancer\n\n      Secondary Objectives:\n\n        1. To describe the use of cabazitaxel  (Jevtana) in combination with oral prednisolone for\n           the treatment of patients with metastatic Hormone Refractory Prostate Cancer\n\n        2. To describe patient profile in terms of demography, disease characteristics and prior\n           treatment history\n\n        3. To describe efficacy outcomes: radiological response (if available) using Recist\n           criteria V 1.1 and Prostate Specific Antigen (PSA) response"
        }, 
        "brief_title": "Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study consists of:\n\n        -  a screening phase (maximum length of 7-day).\n\n        -  a treatment phase with 21-day study treatment cycles. Patients continue to receive\n           treatment until  disease progression , death, unacceptable toxicity, investigator's\n           decision or withdrawal of consent.\n\n        -  a 30-day follow-up visit after the last dose of study medication."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Metastatic hormone refractory prostate cancer (mHRPC) previously treated with a\n             docetaxel-containing regimen\n\n          -  Disease Progression during or after docetaxel-containing regimen for mHRPC\n\n          -  Surgical or medical castration\n\n          -  Patient is \u2265 18 years and \u2264 75 years of age\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n\n          -  Adequate bone marrow, liver, and renal function: Neutrophils> 1500 /mm3; Hemoglobin >\n             10 g/dL; Platelets > 100 x109/L; Bilirubin < Upper Normal Limit (ULN); Serum\n             Glutamate Oxaloacetate Transaminase (Aspartate Aminotransferase)/SGOT (AST) <\n             1.5xULN; Serum Glutamate Pyruvate Transaminase (Alanine Aminotransferase)/SGPT (ALT)\n             < 1.5xULN; Creatinine < 1.5xULN. In case of creatinine > 1.0 x ULN and < or = 1.5 x\n             ULN, calculated creatinine clearance according to CKD-EPI formula should be > or = 60\n             ml/min.\n\n          -  Written informed consent must be obtained prior to any study related procedures\n\n        Exclusion criteria:\n\n          -  Prior radiotherapy to \u2265 40% of bone marrow\n\n          -  Previous treatment with cabazitaxel (Jevtana\u00ae)\n\n          -  Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks\n             prior to enrollment\n\n          -  Active grade \u22652 peripheral neuropathy\n\n          -  Active grade \u22652 stomatitis\n\n          -  Active infection requiring systemic antibiotic or anti-fungal medication\n\n          -  Active cancer (other than mHRPC) including prior malignancy from which the patient\n             has been disease-free for \u22645 years\n\n          -  Known brain or leptomeningeal involvement\n\n          -  History of severe hypersensitivity reaction (\u2265grade 3) to docetaxel\n\n          -  History of severe hypersensitivity reaction (\u2265grade 3) to polysorbate 80 containing\n             drugs\n\n          -  History of severe hypersensitivity reaction (\u2265grade 3) or intolerance to prednisone\n             or prednisolone\n\n          -  Uncontrolled severe illness or medical condition (including uncontrolled diabetes\n             mellitus)\n\n          -  Concurrent or planned treatment with strong inhibitors or strong inducers of\n             cytochrome P450 3A4/5 (a 2 weeks wash-out period is necessary for patients who are\n             already on these treatments). Participation in any other clinical trial with any\n             investigational drug\n\n          -  Patient with reproductive potential not implementing accepted and effective method of\n             contraception\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074137", 
            "org_study_id": "CABAZL06499", 
            "secondary_id": "U1111-1131-3161"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cabazitaxel", 
                "description": "Pharmaceutical form:Solution Route of administration: Intravenous", 
                "intervention_name": "CABAZITAXEL XRP6258", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cabazitaxel", 
                "description": "Pharmaceutical form:Tablet Route of administration: Oral", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cabazitaxel", 
                "description": "Pharmaceutical form:Tablet Route of administration: Oral", 
                "intervention_name": "Prednisolone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 26, 2014", 
        "number_of_arms": "1", 
        "official_title": "Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen", 
        "overall_contact": {
            "email": "Contact-US@sanofi.com", 
            "last_name": "Trial Transparency Team"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with Related Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "up to13 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074137"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluation of use of cabazitaxel in terms of treatment duration, number of cycles, dose modifications", 
                "safety_issue": "No", 
                "time_frame": "up to 13 months"
            }, 
            {
                "measure": "Radiological overall response (if radiological tumor assessment done) using Recist criteria", 
                "safety_issue": "No", 
                "time_frame": "up to 13 months"
            }, 
            {
                "measure": "Number of patients with at least 50% decrease in PSA", 
                "safety_issue": "No", 
                "time_frame": "up to 13 months"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}